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different techniques to deal with missing data was compared.
METHODS: The analysis addressed the global health status
scale (QL range [1;100]) of QLQ-C30, the EQ-5D utility index
(Utility range [0;1]) and Visual Analysis Scale (VAS range
[0;100]). Five multiple imputation (MI) techniques were carried
out with two softwares (SAS, IVEware) and compared with
Rubin’s efﬁciency: Monte-Carlo Markov Chain (MCMC),
Expectation-Maximization (EM), Regression (REG), Propensity
score (PROP) and Sequential regression (SEQ), using 5 simula-
tions per technique. RESULTS: Changes signiﬁcance varied
depending on the imputation technique. At baseline, mean scores
were: QL 0.73, EQ-5D index 63.4, and VAS 68. For QL score,
the change estimations were (mean [95%CI]): -1.699 [-3.322;
-0.076] (MCMC), -1.558 [-3.132; 0.015] (EM), -1.795
[-3.449; -0.141] (REG), -1.197 [-3.067, 0.673] (PROP),
-0.895 [-5.622; 3.832] (SEQ). For EQ-5D index, estimations
were: -0.020 [-0.042; 0.003] (MCMC), -0.018 [-0.043; 0.007]
(EM), -0.018 [-0.034; -0.002] (REG), -0.015 [-0.045; 0.014]
(PROP), -0.010 [-0.049; 0.030] (SEQ). VAS changes varied
from 0.019 (SEQ) to 0.791 (PROP), no change estimation was
signiﬁcant. Rubin’s efﬁciency was comprised between 88.32%
and 94.43% depending on score and technique. CONCLU-
SIONS: Results have to be carefully interpreted since they vary
according to the MI method. SEQ is the only method not assum-
ing a normal distribution of the data and consequently displays
large conﬁdence intervals. Nevertheless, multiple imputation is
told to be robust to normality. A sensitivity analysis is advised in
order to compare the different results.
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STATISTICAL METHODOLOGY IS CRUCIAL IN PROGNOSTIC
FACTOR ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE
Mauer M, Coens C, Bottomley A
European Organisation for Research and Treatment of Cancer
(EORTC), Brussels, Belgium
OBJECTIVES: Whilst a number of systematic reviews (e.g.
Gotay et al in press) have been analyzing prognostic value of
patient-reported outcomes (PROs), including HRQOL, few have
focused on the statistical methods used. In this study, we
reviewed the statistical methods employed and proposed robust
statistical analysis for future PROs studies predicting survival of
cancer patients. METHODS: A total of 49 English articles were
selected from published reviews, conference abstracts, Medline
(1990–2008), various databases and discussions with colleagues
and reviewed during June to December 2007. Each article was
systematically examined for a key set of factors such as design
issues, selection of HRQOL factors, control for clinical factors
along with a detailed extraction of the statistical methods used
for analyzing HRQOL data. Once compiled, we identiﬁed good
practice and recommended approaches for future research.
RESULTS: Most HRQOL prognostic factor analyses, often
within clinical trials, are not deﬁned in protocols. In addition, a
detailed description of the statistical methodology and reporting
of the HRQOL results was often lacking in publications. Infor-
mation regarding sample size, handling missing data and the
veriﬁcation of the model assumptions varied considerably. Pre-
selection of HRQOL factors was not always done. A large
number of HRQOL factors increases the risk of selecting a factor
by chance and model over ﬁtting. In the model building strategy,
several approaches controlled for clinical factors in the analysis,
others allowed clinical factors replacement with (perhaps
slightly) more prognostic HRQOL factors. Model validation was
reported in nine studies. Measures of predictive accuracy were
computed in only seven studies. CONCLUSIONS: Undertaking
HRQOL prognostic factor analysis is a challenge. The priority is
validation and careful use of techniques and providing proof that
the addition of HRQOL indicators signiﬁcantly increases the
prediction of survival in cancer patients. We hope our work will
highlight these opportunities.
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THE IMPACT OF INSULIN DETEMIR COMPAREDTO NEUTRAL
PROTAMINE HAGEDORN INSULIN ON LONG-TERM
DIABETES-RELATED COMPLICATIONS:A MODELING
ANALYSIS INTYPE 1 DIABETES PATIENTS IN BELGIUM,
FRANCE, GERMANY, ITALY AND SPAIN
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OBJECTIVES: The aim of this analysis was to evaluate the time
to onset and long-term cumulative incidence of diabetes-related
complications in type 1 diabetes patients receiving either insulin
detemir or Neutral Protamine Hagedorn (NPH) insulin in com-
bination with mealtime insulin aspart in ﬁve countries (Belgium,
France, Germany, Italy and Spain). METHODS: A published and
validated computer simulation model of diabetes (CORE Diabe-
tes Model) was used to make long-term projections of clinical
outcomes, based on patient characteristics and treatment effects
from a 2-year, multi-national, open-label, randomized, con-
trolled trial. In the trial, insulin detemir was associated with
signiﬁcant improvements in glycemic control after 24 months
(HbA1c 7.36% versus 7.58%, mean difference -0.22%,
P = 0.022) and major hypoglycemic events (69% risk reduction,
P = 0.001) versus NPH. Patients treated with detemir gained less
weight (1.7 versus 2.7 kg, P = 0.024). Events were projected for
a time horizon of 50 years. RESULTS: Basal-bolus therapy with
insulin detemir was projected to improve mean life expectancy by
0.09 years (12.80 versus 12.71 years) versus NPH in Germany.
Similar beneﬁts were observed in the other countries
(Belgium + 0.14, France + 0.13, Italy + 0.15 and Spain + 0.07
years). The time to onset of any diabetes-related complication
was delayed by 0.08 years in the detemir arm (1.18 versus 1.10
years). Time to onset and cumulative incidence (CI) of diabetic
eye and renal disease, neuropathy and amputations were gener-
ally decreased for detemir-based therapy, with greatest beneﬁts
observed in renal disease. The CIs of heart failure, angina and
stroke were slightly raised in the detemir-based treatment arm as
overall survival was increased, exposing these patients to a longer
ongoing risk of these events. CONCLUSIONS: The modelling
analysis suggests that insulin detemir is likely to improve life
expectancy, delay the onset of and reduce the cumulative inci-
dence of most diabetes related complications in type 1 diabetes
patients.
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INSULIN NPHTO INSULIN GLARGINE:A RETROSPECTIVE
OBSERVATIONAL STUDY
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OBJECTIVES: This study investigated the effect on glycaemic
control of switching from a NPH-based regimen to a glargine-
based regimen in 701 patients with type 1 (T1) (n = 304) or type
2 (T2) (n = 397) diabetes, using unselected primary care data.
METHODS: Data for this retrospective observational study were
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extracted from a UK primary care database (The Health
Improvement Network). Patients were required to have at least
12 months of data before and after switching. The principle
analysis was the change in HbA1c; secondary analyses included
change in weight and insulin dose. Hypoglycaemia could not be
assessed due to inconsistency in the recording of episodes. Mul-
tivariate analyses were used to adjust for baseline characteristics
and confounding variables. RESULTS: Mean HbA1c levels at
baseline were similar in the T1 and T2 cohorts (8.8% and 8.9%
respectively). After adjustment, both diabetic cohorts showed
statistically signiﬁcant reductions in mean HbA1c 12 months after
switch, by 0.38% (p < 0.001) in T1 and 0.31% (p < 0.001) in T2
patients. Improvement in HbA1c was positively correlated with
baseline HbA1c; patients with baseline HbA1c  8% had reduc-
tions of 0.57% (p < 0.001) and 0.47% (p < 0.001), respectively.
There was no signiﬁcant change in weight or total daily insulin
dose while on glargine. The majority of patients received a basal-
bolus regimen prior to and after switch (mean 79.3% before and
77.2% after switch in T1 patients and 80.4% and 76.8%, respec-
tively in T2 patients, p > 0.05). CONCLUSIONS: In routine
clinical practice, switching from NPH to glargine provides the
opportunity for improving glycaemic control in diabetes patients
inadequately controlled by NPH.
PDB3
SWITCHING FROM PREMIXED INSULINTO INSULIN
GLARGINE-BASED REGIMEN IMPROVES GLYCAEMIC
CONTROL IN PATIENTS WITHTYPE 1 ORTYPE 2 DIABETES:
A RETROSPECTIVE PRIMARY CARE-BASED ANALYSIS
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OBJECTIVES: To investigate the effect on glycaemic control of
switching from a premix-based regimen to a glargine-based
regimen in 528 patients with type 1 (n = 183) or type 2 (n = 345)
diabetes, using unselected primary care data from a UK database
(The Health Improvement Network). METHODS: Patients were
required to have at least 12 months of available data, before and
after switching. The principle analysis was the change in HbA1c;
secondary analyses included change in weight, bolus usage and
insulin dose. Hypoglycaemia could not be assessed due to lack of
consistency in the recording of episodes. Multivariate analyses
were used to adjust for baseline characteristics and confounding
variables. RESULTS: Mean HbA1c levels at baseline were similar
in the T1 and T2 cohorts (9.4% and 9.3% respectively). After
adjustment both cohorts showed signiﬁcant reduction in mean
HbA1c 12 months after the switch: by -0.67% (p < 0.001) in the
T1 cohort and by -0.53% (p < 0.001) in the T2 cohort. Patients
with a baseline HbA1c  10% had the greatest reduction in
HbA1c, by -1.7% (p < 0.001) and -1.2% (p < 0.001), respec-
tively. Proportion of patients receiving a co-bolus prescription
went from 24.6% on premix to 95.1% on glargine in the T1
cohort, p < 0.001 and from 16.2% to 73.9% in the T2 cohort,
p < 0.001. There was no signiﬁcant change in weight in the T2
cohort with a moderate increase in T1 patients (0.3 kg and 3.7 kg
respectively, p > 0.05). Total insulin use (SD) increased in T2
patients (0.67  1.35 IU/Kg to 0.88  1.33 IU/Kg, p < 0.001)
with no signiﬁcant increase in T1 diabetes patients. CONCLU-
SIONS: In everyday practice, patients with T1 or T2 diabetes
inadequately controlled by premix insulins experienced signiﬁ-
cant improvement in glycaemic control over 12 months after
switching to a glargine-based regimen. These ﬁndings support the
use of glargine plus boluses in patients poorly controlled on
premix.
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OBJECTIVES: The control of blood glucose improves the long
term outcomes for patients with type 2 diabetes; this study exam-
ined the levels of glycemic control in a clinic at MSFHCC, Saudi
Arabia. METHODS: Data were obtained from patient medical
records. All patients who met the inclusion criteria: (with type 2
diabetes, made at least four visits during one year, had their
glycated hemoglobin (A1c) level been checked), the time frame
for sampling is 18 months ending in December 2007. Descriptive
statistics, logistics regression, and ANOVA were used in the
analysis. RESULTS: Four hundred nine patients’ records met the
inclusion criteria, male are 64.7% of the sample, the means for
age, A1c, BMI, and the duration of the DM were 53.4, 8.3%,
30.6 and 9.3 years, respectively. A total of 24.9% of the sample
has A1c at the target control level (<7%), the test of differences
of means of age, BMI and Duration of having DM across the
levels of A1c (controlled , not well controlled (7%  A1c < 8.5),
and poorly controlled (A1c  8.5)) did show consistent results
except BMI variable, group at the controlled HbA1c level has
signiﬁcant higher BMI means than the group with poorly con-
trolled A1c level. 13.2% of the sample treated with oral mono-
therapy antidiabetic drugs, 25.6% with a combination of Insulin
and Metformin, and the rest were with multitherapy. In the
logistic regression model, the type of therapy and the duration of
diabetes were signiﬁcant predictors for whether patient has con-
trolled A1c level. CONCLUSIONS: The high rate of uncon-
trolled diabetic patients is an evidence of shortcoming. Large
data might provide much and precise information to explain this
high rate. The unexpected relationship between BMI and A1c
level which noticed in controlled group could be explained by
short duration of diabetes, early aggressive therapy regimens or
other pathophysiological factors. Further follow up of such con-
trolled group may provide an explanation of such relationship.
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GLARGINE OR DETEMIR IN PATIENTS WITHTYPE 2
DIABETES MELLITUS- AN ANALYSIS OF ELECTRONIC
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OBJECTIVES: We examined glycemic outcomes in patients with
type 2 diabetes (T2D) initiated to insulin glargine (GLAR) or
detemir (DET) using electronic medical records (EMR) from a
specialty practice in Baltimore, US. METHODS: Patients’ EMRs
using GLAR (n = 134) or DET (n = 88) between January 2005–
2007 with at least 4 available clinic visits were evaluated. Each
patient on DET was matched with one or more patients on
GLAR by baseline HbA1c. Average follow-up time was 6 months
RESULTS: Patients were similar in age (59 vs 60 years), HbA1c
(8.65 vs 8.46%), and BMI (33.6 vs 33.7 kg/m2) but differed in
T2D duration (12.9 vs 10years, P = 0.03) and gender (female 58
vs 44%, P = 0.04) between GLAR and DET, respectively. Prior
use of antidiabetic drugs was similar except for a higher percent-
age of patients using premixed insulin in GLAR (24.8% vs 8.9%
[DET], P = 0.004) and of patients using exenatide in DET
(32.9% vs 6.2 % [GLAR], P = 0.0001). Unadjusted A1C values
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